1b192a49-01cb-4459-a7a7-fdebe428f386
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INTERFERON_ALPHA_RESPONSE+0.490
- HEDGEHOG_SIGNALING+0.460
- ANGIOGENESIS+0.450
- INFLAMMATORY_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.410
- IL6_JAK_STAT3_SIGNALING+0.400
- KRAS_SIGNALING_UP+0.390
- UV_RESPONSE_DN+0.370
- COAGULATION+0.340
Top 10 suppressed
- E2F_TARGETS-0.680
- MYC_TARGETS_V1-0.640
- OXIDATIVE_PHOSPHORYLATION-0.620
- G2M_CHECKPOINT-0.580
- MYC_TARGETS_V2-0.540
- DNA_REPAIR-0.490
- MTORC1_SIGNALING-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.330
- GLYCOLYSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.945 |
| 2 | TCGA-55-7227-01A-11R-2039-07 | — | cohortA1 | 0.929 |
| 3 | SRR12202441 | — | — | 0.928 |
| 4 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.928 |
| 5 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.927 |
| 6 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.924 |
| 7 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.923 |
| 8 | cbd54c6f-2634-4ac6-ba5a-73cb4680867a | — | — | 0.922 |
| 9 | C3L-02515 | — | cohortA1 | 0.922 |
| 10 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |